EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class…
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4…
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4…
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4…
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR…
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FASTs 17th Annual Global Science Summit
November 09, 2024 10:30 ET | Source: Ultragenyx Pharmaceutical Inc. Phase 1/2…
Biologic Pharmamedical Reveals Capryl-Butyrate and necessary lifestyle changes for natural solutions for Gut Health, Mental Clarity, and Age-Defying Wellness
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Biologic Pharmamedical™ Research…